
Onvida Health and Ambience Healthcare Partner to Enhance Patient Care and Revolutionize Clinical Workflows with AI Technology
YUMA, AZ / ACCESS Newswire / May 19, 2025 / Onvida Health, a leading provider of integrated care throughout Arizona, and Ambience Healthcare, the leading AI platform for clinical documentation, CDI, and coding, today announced the launch of a pilot program across multiple clinical sites.
Onvida Health clinicians across outpatient, inpatient, and emergency department settings will be piloting Ambience's suite of AI applications to generate comprehensive and compliant documentation in real time-directly within Epic's Electronic Health Record (EHR).
The pilot, launching in June 2025, reflects Onvida Health's ongoing commitment to delivering the highest quality care in the region-while supporting clinicians with innovative technology to improve efficiency, reduce burnout, and increase time with patients.
With this technology, Onvida Health providers will spend less time on administrative work and more time with patients-while strengthening documentation integrity, supporting compliance, and improving financial accuracy.
"We are investing in the most advanced AI platform in healthcare because we believe the best patient care starts with supporting our clinicians," said Marc Chasin, M.D., Senior Vice President and Chief Information Officer at Onvida Health. "Ambience will allow our clinicians to spend less time on paperwork and more time with their patients-while improving quality, accuracy and compliance."
Ambience's suite of AI applications includes:
Scribing: The only AI medical scribe built to support the medicine, workflows, and coding and billing requirements of more than 100 specialties and subspecialties, including inpatient and emergency medicineCDI: A point-of-care CDI assistant that analyzes conversations and surfaces precise ICD-10 codes, CPT codes, and full audit trails for revenue cycle teamsPatient Summaries: Comprehensive summaries for patients, their families, and caretakersReferrals: Clinically relevant and well-organized referral letters for primary care clinicians and specialists
Ambience's AI platform helps clinicians design their agenda before a patient visit begins. Once the clinician is in the room with a patient, Ambience listens to the conversation. The technology then leverages all of the patient's historical EHR data, as well as the recording of the visit, to automate documentation for the patient and clinician. This includes clinical notes, after-visit summaries, referral letters, and CPT and ICD-10 coding suggestions.
"By equipping our clinicians with Ambience's AI technology, we're ensuring that every patient receives more personalized attention, more thorough care, and a better overall experience," said Kristina Diaz, M.D., President of Onvida Health Medical Group. "This partnership is about giving our patients and clinicians the time, focus, and quality they deserve-putting the human connection back at the center of every visit."
Clinicians at leading health systems across North America leverage Ambience before, during, and after patient encounters. Ambience has been deployed at Cleveland Clinic, UCSF Health, St. Luke's Health System, Houston Methodist, John Muir Health, Memorial Hermann Health System, and others.
"We are honored to partner with Onvida Health, an organization deeply committed to putting patients first, supporting their providers, and driving innovation," said Mike Ng, CEO and Co-Founder of Ambience Healthcare. "Today, clinicians spend only about a quarter of their time on direct patient care - and together with Onvida Health, we are going to change that. By supporting every clinical encounter with Ambience's AI technology, we're helping clinicians reclaim their time, enhance compliance and accuracy, and refocus healthcare around what matters most: the patient."
About Onvida Health
Onvida Health is a not-for-profit hospital system with 430 inpatient beds, 45 outpatient clinics and a free-standing Emergency Department. The Onvida Health team includes 495 providers representing 52 specialties, 4000 employees and hundreds of volunteers who work closely together to create a welcoming, caring and compassionate environment for patients and their families. Onvida Health is dedicated to building a healthier tomorrow for Yuma County residents and the surrounding southwestern Arizona communities.
About Ambience HealthcareAmbience Healthcare's mission is to supercharge healthcare providers with breakthrough generative AI technology. Ambience's products are currently leveraged by leading provider organizations and health systems across North America to reduce documentation burden, alleviate provider burnout, and improve care quality. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco, California, and backed by Andreessen Horowitz, OpenAI Startup Fund, Human Capital, Kleiner Perkins, Martin Ventures, AIX Ventures, AirTree Ventures, John Doerr, Jeff Dean, Richard Socher, Pieter Abbeel, Anne Wojcicki, Eren Bali, Jay Desai, Nish Bhat, Matt Mochary, and others. To learn more, visit ambiencehealthcare.com.
For more information, press only:
Karina StabileAria Marketing for Ambience Healthcarekstabile@ariamarketing.com516-317-5835
Jenn Lotz Williams(504) 376-3253Jwilliams4@onvidahealth.org
SOURCE: Ambience
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Indianapolis Star
15 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire

Associated Press
19 hours ago
- Associated Press
Armenia's .AM Domain Comes On-Chain via WebUnited: Live Reveal and Workshop at ICANN 83 in Prague
WebUnited will host two exclusive Web3 workshops during ICANN 83 in Prague. Tailored for registrars, registries, and digital identity innovators, the sessions will take place on June 10 and June 11 from 16:00 to 18:00 CEST at the Grand Hotel Prague Towers, 24th Floor, followed by drinks, canapés, and skyline networking. PRAGUE, CZ / ACCESS Newswire / June 6, 2025 / In a landmark moment for the global domain name industry, Armenia Domains has announced that the country's .am ccTLD is now being mirrored on-chain in collaboration with WebUnited, signaling a major step toward DNS and blockchain integration. 'Bringing .am on-chain is more than a technical upgrade - it's a strategic move to keep ccTLDs future-ready,' said Nick Cervantes, CEO of 'We're proud to be among the first to enable blockchain functionality through DNS infrastructure, and we believe this is just the beginning.' Workshop Agenda: DNS Domains Meet Web3 Utility WebUnited's mission is simple: enable registrars to add Web3 functionality to any DNS domain name, without disrupting existing systems. These sessions will demonstrate how domains can now: • Function as human-readable crypto wallet addresses • Act as a Web3 identity anchor • Help registrars unlock new revenue streams and retain users in a rapidly evolving ecosystem Live Demo Highlights: • Step-by-step domain mirroring on-chain • Connecting crypto wallets to domain names • Viewing mirrored domains in MetaMask No prior Web3 experience needed. The format is designed to be light, hands-on, and interactive, with experts available for more in-depth technical questions. Featured Panel: Real Voices, Real Insights Each session will include a 30-minute panel discussion with industry experts, including: • Nick Cervantes, CEO of shares how the .am ccTLD is moving on-chain • Daniel Greenberg, CEO of Lexsynergy, on how registrars are preparing brands for Web3 • Gherardo Varani, Head of Business Development at Freename, on adoption trends across Web3 users • Moderated by Kathy Nielsen, domain expert and industry advisor 'WebUnited isn't just building tools - it's building bridges between two powerful worlds,' said Lars Jensen, CEO of WebUnited. 'We're helping registrars future-proof their offering and stay relevant in the age of blockchain, without needing to start from scratch.' Networking Reception After each workshop, guests are invited to unwind with drinks, canapés, and conversations overlooking the Prague skyline - all from the stunning 24th floor of the Grand Hotel Prague Towers. Seats are limited - register early to secure your spot. Reserve your seat now About WebUnited WebUnited empowers domain name registrars to offer Web3 functionality by mirroring DNS domains on-chain. This enables registrants to use their existing domain names for blockchain identity, wallet naming, decentralized publishing, and more, with zero disruption to their Web2 presence. Media Contact [email protected] Contact InformationEshan Pancholi SOURCE: WebUnited press release
Yahoo
a day ago
- Yahoo
How Will Quantum Technologies Transform the $9.8 Trillion Global Healthcare Sector?
A recent publication by quantum researcher Ali Karakuş draws the attention of the medical industry. BERLIN, DE / / June 5, 2025 / Quantum researcher Ali Karakuş has published a groundbreaking scientific paper that challenges the foundations of modern medicine and proposes a bold new perspective on health. The study introduces a next-generation medical model based on quantum sensors, ethical artificial intelligence, and resonance-based diagnostics-aiming to redefine our understanding of illness and healing. Global healthcare expenditures now exceed $9.8 trillion per year. Yet, despite this enormous financial investment, chronic illnesses, mental health disorders, and stress-related conditions are on the rise. According to Karakuş, the problem is not technological scarcity but the loss of harmonic alignment between humans, nature, and their own bodies. "We measure numbers but fail to listen to frequencies," says Karakuş. "We treat symptoms, yet overlook resonance breakdowns. The body must no longer be viewed as matter alone, but as a field of waves and energy." From Symptom Suppression to Resonance Restoration At the heart of the study is a quantum-sensor-based device in development that analyzes brainwaves, heart rate variability (HRV), vagus nerve activity, microbiome signals, and ethical resonance scores. All of this data is then processed by an ethical AI engine called Zulficore, producing a holistic and personalized feedback loop. A New Question for Medicine: "What's wrong?" or "What's out of tune?" The system designed by SlientWing integrates multiple disciplines including quantum biology, neuroscience, biomimetics, ecological AI, and ethics-based algorithms. The core question is shifting: Not "What disease do you have?" But "What frequency is disturbed? Which resonance with nature is lost?" Launch Timeline The beta version of the SlientWing device is expected to be field-tested by late 2026, with full-scale production and market launch scheduled for 2027. Manufacturing will be centered in Berlin and Thrace. Contact Information Ali Karakus Founderali@ SOURCE: Neuroscience & Quantum Researcher Ali Karakus View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data